

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2007 (04.01.2007)

PCT

(10) International Publication Number
WO 2007/000434 A1

(51) International Patent Classification:

A61K 31/4353 (2006.01) C07D 215/227 (2006.01)
A61P 31/04 (2006.01) C07D 215/36 (2006.01)

(21) International Application Number:

PCT/EP2006/063552

(22) International Filing Date: 26 June 2006 (26.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

05105755.2 28 June 2005 (28.06.2005) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANDRIES, Koenraad, Jozef, Lodewijk, Marcel [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). KOUL, Anil [IN/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LANÇOIS,




David, Francis, Alain [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, A division of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR). MOTTE, Magali, Madeleine, Simone [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, A division of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR). GUILLEMONT, Jérôme, Emile, Georges [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, A division of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR).

(74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

[Continued on next page]

(54) Title: QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS



(57) Abstract: Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula (Ia) or (Ib) a N-oxide, a tautomeric form or a stereochemically isomeric form thereof. The compounds themselves are also claimed as well as their combinations with other antibacterial agents.



NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC,
SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.